chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 59.0
Sex: F
Vaccine: FLUR4
Symptoms: Fatigue, Malaise, Pain, Polymyalgia rheumatica, Pyrexia
Clinical narrative: She was diagnosed with PMR (polymyalgia rheumatica); Four hours later she started to have symptoms of: body and joint pain; Four hours later she started to have symptoms of: body and joint pain; patient had fever; weak; patient had confused; patient had no appetite; patient started to have light headedness; patient had symptom of fatigue; patient had malaise; patient had trigeminal neuralgia; Initial information received on 09-May-2022 regarding an unsolicited valid  serious case received from a patient via call center.   This case involves a 59 years old female patient who experienced she was diagnosed with pmr (polymyalgia rheumatica) and patient had trigeminal neuralgia while receiving vaccine influenza quadrivalent recombinant vaccine [FLUBLOK QIV].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 05-Oct-2021, the patient received a  dose of suspect influenza quadrivalent recombinant vaccine (lot UJ725AA) (dose, formulation, strength, and expiry date: unknown) via intramuscular route in unknown administration site for Flu vaccination.   On 05-OCT-2021 the patient developed a serious she was diagnosed with pmr (polymyalgia rheumatica) with symptom [body and joint pain (pain and arthralgia), pyrexia, asthenia, confused (confusional state), no appetite (decreased appetite), light headedness (dizziness), fatigue asthenia and malaise] (latency 4 hours) following the administration of influenza quadrivalent recombinant vaccine.  On 05-OCT-2021 the patient developed a non-serious patient had trigeminal neuralgia (trigeminal neuralgia) (latency 4 hours) following the administration of influenza quadrivalent recombinant vaccine.   Seriousness- medically significant for polymyalgia rheumatic   trigeminal neuralgia (non- serious)  Action taken: not applicable.  The patient was treated with prednisone for Polymyalgia rheumatica and Trigeminal neuralgia.  Outcome- Recovered / Resolved for Polymyalgia rheumatica and Trigeminal neuralgia; Sender's Comments: Sanofi Company Comment dated 16-May-2022: This case involves a 59 years old female patient who experienced she was diagnosed with pmr (polymyalgia rheumatica) while receiving vaccine influenza quadrivalent recombinant vaccine [FLUBLOK QIV]. The causal role of the company suspect drug cannot be excluded based on the temporal relevance instead of the time to onset is compatible with the role of the vaccine. However, information regarding condition at the time of vaccination, lab data excluding other predisposing etiologies would be needed for complete assessment of the case. Based upon the reported information, the role of  vaccine cannot be assessed.
Age: 59.0
Sex: F
Vaccine: FLUR4
Symptoms: Trigeminal neuralgia
Clinical narrative: She was diagnosed with PMR (polymyalgia rheumatica); Four hours later she started to have symptoms of: body and joint pain; Four hours later she started to have symptoms of: body and joint pain; patient had fever; weak; patient had confused; patient had no appetite; patient started to have light headedness; patient had symptom of fatigue; patient had malaise; patient had trigeminal neuralgia; Initial information received on 09-May-2022 regarding an unsolicited valid  serious case received from a patient via call center.   This case involves a 59 years old female patient who experienced she was diagnosed with pmr (polymyalgia rheumatica) and patient had trigeminal neuralgia while receiving vaccine influenza quadrivalent recombinant vaccine [FLUBLOK QIV].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 05-Oct-2021, the patient received a  dose of suspect influenza quadrivalent recombinant vaccine (lot UJ725AA) (dose, formulation, strength, and expiry date: unknown) via intramuscular route in unknown administration site for Flu vaccination.   On 05-OCT-2021 the patient developed a serious she was diagnosed with pmr (polymyalgia rheumatica) with symptom [body and joint pain (pain and arthralgia), pyrexia, asthenia, confused (confusional state), no appetite (decreased appetite), light headedness (dizziness), fatigue asthenia and malaise] (latency 4 hours) following the administration of influenza quadrivalent recombinant vaccine.  On 05-OCT-2021 the patient developed a non-serious patient had trigeminal neuralgia (trigeminal neuralgia) (latency 4 hours) following the administration of influenza quadrivalent recombinant vaccine.   Seriousness- medically significant for polymyalgia rheumatic   trigeminal neuralgia (non- serious)  Action taken: not applicable.  The patient was treated with prednisone for Polymyalgia rheumatica and Trigeminal neuralgia.  Outcome- Recovered / Resolved for Polymyalgia rheumatica and Trigeminal neuralgia; Sender's Comments: Sanofi Company Comment dated 16-May-2022: This case involves a 59 years old female patient who experienced she was diagnosed with pmr (polymyalgia rheumatica) while receiving vaccine influenza quadrivalent recombinant vaccine [FLUBLOK QIV]. The causal role of the company suspect drug cannot be excluded based on the temporal relevance instead of the time to onset is compatible with the role of the vaccine. However, information regarding condition at the time of vaccination, lab data excluding other predisposing etiologies would be needed for complete assessment of the case. Based upon the reported information, the role of  vaccine cannot be assessed.
Sex: U
Vaccine: FLU4
Symptoms: Product storage error
Clinical narrative: 1 patient received FLUZONE QIV T 8 days after 06-Apr-2022 (when product was no longer suitable for use): 8 days after a temperature excursion with no adverse event; Initial information received on 10-May-2022 regarding an unsolicited valid  non-serious case received from a other health professional. This case is related to case id: 2022SA168646  This case involves an unknown age and unknown gender patient, that 1 patient received fluzone qiv t 8 days after 06-apr-2022 (when product was no longer suitable for use): 8 days after a temperature excursion with no adverse event while receiving vaccine influenza quadrival a-b multidose vaccine preserved [Fluzone quadrivalent multidose].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect influenza quadrival a-b multidose vaccine  preserved suspension for injection (lot number, strength, expiry date: not reported) via unknown route in unknown administration site as prophylactic vaccination.  Influenza quadrival a-b multidose vaccine preserved TT experienced 3 temperature excursions. Conditions of excursions were on 6-Apr-2022 8.1 C 8 minutes 8-Apr-2022, 9.6 C 59 minutes 11-Apr-2022 9.1 C 56 minutes and cumulative total time of 123 minutes.   There was a minor excursion of 8.1 C for 8 minutes; states when she called Merck, they told her that they round to the nearest whole number, so they did not consider the event on 06-Apr-2022 to be an excursion. Caller stated that this will affect her influenza quadrival a-b multidose vaccine preserved since it was only suitable for use for 1 week beginning after the first excursion. Caller asked if 1 week started on 06-Apr-2022 or on 08-Apr-2022. Agent informed caller that Sanofi does not round to the nearest whole number; informed caller that 8.1C would still be considered a temperature excursion and 1 week would begin on 06-Apr-2022.   On 14-Apr-2022, the patient received influenza quadrival a-b multidose vaccine preserved T 8 days after 06-apr-2022 (when product was no longer suitable for use): 8 days after a temperature excursion (product storage error) with no adverse event (unknown latency).  Action taken : not applicable.  At time of reporting, the outcome was Unknown .  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: F
Vaccine: DTAPIPVHIB
Symptoms: No adverse event, Product preparation error, Product preparation issue
Clinical narrative: mixed  the ACTHIB with sterile water and administered it/  DTAP/IPV portion was never administered with no reported adverse event; Initial information received on 11-May-2022 regarding an unsolicited valid  non-serious case received from a consumer/non-hcp.  This case involves a 100 years old female patient and it was reported that "mixed  the ACTHIB with sterile water and administered it/  DTAP/IPV portion was never administered with no reported adverse event", while receiving vaccine DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included HEPATITIS B VACCINE (HEPATITIS B VACCINE); ROTAVIRUS VACCINE (ROTAVIRUS VACCINE); and PNEUMOCOCCAL VACCINE CONJ 13V (CRM197) (PREVNAR 13).  On 09-May-2022, the patient received a  dose of 0.5 ml of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE , (lot : UJ621AAA ; expiry date: 28-Jan-2023) via intramuscular route in the right thigh for immunization.  It was reported that on 09-May-2022, the medical assistant went to administer Pentacel to a patient and was confused because she saw the powdered ACTHIB and removed it from box and did not notice the diluent with DTAP/IPV in the box. She mixed the ACTHIB with sterile water and administered it and DTAP/IPV portion was never administered (product preparation issue) (latency: unknown). The patient did not experience any adverse event as a result of this.  Action taken : not applicable.  Outcome: unknown  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 17.0
Sex: M
Vaccine: MNQ
Symptoms: No adverse event, Wrong product administered
Clinical narrative: the patient was scheduled for 2nd dose of Bexsero but was given MENQUADFI instead with no reported adverse event; Initial information received on 12-May-2022 regarding an unsolicited valid non-serious case received from a other health professional via call center.  This case involves a 17 years old male patient who was scheduled for 2nd dose of bexsero, but was given menquadfi instead with no reported adverse event while receiving vaccine Meningococcal A-C-Y-W135 (T Conj) Vaccine [Menquadfi].  The patient's past medical treatment included Menactra in 2016. The patient's past medical history, vaccination(s) and family history were not provided. Concomitant medications included Meningococcal Vaccine B Rfhbp/Nada/Nhba Omv (Bexsero) for Immunisation.  In April 2022, the patient received a dose of suspect meningococcal a-c-y-w135 (t conj) vaccine lot number not reported (dose number: one) (strength, dose, route, administration site, expiry date and formulation: unknown). On 11-May-2022 he also received 0.5 ml of the same vaccine lot U6821AA via intramuscular route in the left arm (strength, expiry date and formulation: unknown) both for immunization.  On 11-MAY-2022, the patient developed a non-serious event the patient was scheduled for 2nd dose of bexsero but was given menquadfi instead with no reported adverse event (wrong product administered) (latency: same day) following the administration of meningococcal A-C-Y-W135 (t conj) vaccine.  Action taken was not applicable.  It was not reported if the patient received a corrective treatment for the event (wrong product administered).  At time of reporting, the outcome was Unknown for the event the wrong product administered.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Glossodynia, Nausea, Ocular hyperaemia, Pharyngeal erythema
Clinical narrative: She stated approximately 12 minutes after receiving dose #1 Covid, she told the RN at the facility her tongue was stinging.  The nurse had her go to another area and her symptoms started to change.  Her eyes became red, she had increased mucus forming in her throat, her throat became red and scratchy, and she started coughing because of the increased mucus in her throat. She was given an injection 25 mg of Benadryl and transported to the ER. She was treated with Decadron at the ER, given an epipen to take home. She stated she felt nauseated the next day but had no other symptoms. She followed up with her primary care and the allergy clinic.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Secretion discharge, Skin test, Throat irritation
Clinical narrative: She stated approximately 12 minutes after receiving dose #1 Covid, she told the RN at the facility her tongue was stinging.  The nurse had her go to another area and her symptoms started to change.  Her eyes became red, she had increased mucus forming in her throat, her throat became red and scratchy, and she started coughing because of the increased mucus in her throat. She was given an injection 25 mg of Benadryl and transported to the ER. She was treated with Decadron at the ER, given an epipen to take home. She stated she felt nauseated the next day but had no other symptoms. She followed up with her primary care and the allergy clinic.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Chest discomfort, Cough, Dyspnoea, Fall
Clinical narrative: Systemic: Allergic: Difficulty Breathing-Medium, Systemic: Fainting / Unresponsive-Severe, Systemic: Shakiness-Medium, Systemic: Weakness-Medium, Additional Details: Patient sat on bench after receiving vaccine, then fell to the floor from the seated position. She was coughing while unconscious but eventually came to when her name was called out. She described a heavy pressure feeling on her chest and had difficulty breathing, but recovered relatively quickly (~10-15 minutes).
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Loss of consciousness, Syncope, Tremor, Unresponsive to stimuli
Clinical narrative: Systemic: Allergic: Difficulty Breathing-Medium, Systemic: Fainting / Unresponsive-Severe, Systemic: Shakiness-Medium, Systemic: Weakness-Medium, Additional Details: Patient sat on bench after receiving vaccine, then fell to the floor from the seated position. She was coughing while unconscious but eventually came to when her name was called out. She described a heavy pressure feeling on her chest and had difficulty breathing, but recovered relatively quickly (~10-15 minutes).
Age: 15.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoaesthesia, Injection site pain, Paraesthesia
Clinical narrative: Site: Pain at Injection Site-Severe, Systemic: Numbness (specify: facial area, extremities)-Severe, Systemic: Tingling (specify: facial area, extemities)-Severe
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Syncope, Unresponsive to stimuli
Clinical narrative: Systemic: Fainting / Unresponsive-Severe, Additional Details: Wife came into pharmacy to mention patient fainted at home after receiving injection and had to go to emergency room
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Blister, Rash
Clinical narrative: Systemic: Allergic: Rash Generalized-Medium, Systemic: "blistering all over the body"-Medium
Age: 7.0
Sex: M
Vaccine: COVID19
Symptoms: Injury associated with device
Clinical narrative: Error: Patient Accidentally Stuck by Needle-
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Pfizer 3/5/21, 3/26/21, 12/15/21. Positive on 5/12/22
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Complication associated with device, Fatigue, Fluid retention
Clinical narrative: Significant breakthrough with IUD.  Twice a month. Fatigue, Water Retention, and low back pain since July 2021.
Age: 65.0
Sex: M
Vaccine: UNK
Symptoms: Chills, Injection site pain, Nausea
Clinical narrative: Soreness in shot location, shivering, nausea, no fever
Age: 5.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Product preparation issue
Clinical narrative: TEMP 100.0  the following day 5/14/22 and a slightly sore arm PATIENT WAS GIVEN AN UNDILUTED DOSE OF COVID (5-11)
Age: 11.0
Sex: M
Vaccine: COVID19, MEN, TDAP
Symptoms: Incorrect dose administered, No adverse event, Product preparation error
Clinical narrative: Pt was given the 0.2 ml of the pfizer vaccine that was not diluted/mixed before administering by a new medical assistant. The pt did not have any adverse reactions and the provider was notified before the pt left the office and was able to speak with the mom about the medication error.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Exposure to SARS-CoV-2, Malaise, SARS-CoV-2 test positive
Clinical narrative: Experienced pretty severe symptoms the two days following vaccine. Exposed to Covid on May 7 and tested positive on May 12. Was prescribed Paxlovid for symptoms.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Fall, Insomnia, Loss of consciousness, Pain in extremity
Clinical narrative: Pain in arm, shoulders, knees-within 3 hours after vaccination, difficulty sleeping-resolved in 24 hours;  Temporary blackout and fainting with fall from a standing position-13 hours after vaccination, ambulance called,vitals normal (temperature 97.9, bp & heart rate normal.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Syncope
Clinical narrative: Pain in arm, shoulders, knees-within 3 hours after vaccination, difficulty sleeping-resolved in 24 hours;  Temporary blackout and fainting with fall from a standing position-13 hours after vaccination, ambulance called,vitals normal (temperature 97.9, bp & heart rate normal.
Age: 5.0
Sex: M
Vaccine: DTAPIPVHIB
Symptoms: No adverse event, Wrong product administered
Clinical narrative: Patient received a Pentacel instead of a Quadracel. No adverse reactions occured
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Unevaluable event
Clinical narrative: HOSPITALIZATION
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Unevaluable event
Clinical narrative: HOSPITALIZATION
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus
Age: 3.0
Sex: M
Vaccine: PNC13
Symptoms: Injection site pain, Urticaria papular, Vomiting
Clinical narrative: urticarial spotty eruptions on the upper part of both arms and says his leg is very sore where he was given the Prevnar 13 vaccine .  He vomited large amounts
Age: 80.0
Sex: F
Vaccine: FLUA4
Symptoms: Acute myocardial infarction, Acute respiratory failure, Angiogram pulmonary abnormal, COVID-19, Cough
Clinical narrative: Discharge Provider:  Primary Care Provider:  Admission Date: 5/7/2022 Discharge Date: May 12, 2022  PRESENTING PROBLEM: Acute respiratory failure with hypoxia [J96.01] Type 2 myocardial infarction [I21.A1] Acute hypoxemic respiratory failure due to COVID-19 [U07.1, J96.01] COVID-19 virus infection [U07.1]   HOSPITAL COURSE:   This is an 80-year-old female patient who presented with a 5 day history of cough and progressive shortness of breath which escalated on the morning of admission.  At home she had pulse oximetry reading that were severely low, along with profound tachypnea and severe coughing paroxysms.  Her daughter called EMS immediately and EMS found her pulse oximetry reading to be 50% on increase in her supplemental oxygen.  They placed her on BIPAP because of the severity of her dyspnea and her pulse oximetry readings and brought her to ED.  The patient's BIPAP was maintained with an FiO2 of 100%.  She was given Solumedrol and Nebulizer treatments.  She tested + for COVID.  She is vaccinated and has received a booster.  She had an elevated D dimer which prompted a CTA of the thorax that revealed bilateral interstitial pneumonia, ? Consolidative process, previous lobectomies from lung adenocarcinoma, and bronchial inflammation, but no pulmonary embolism.   She was admitted and treated with oxygen therapy after weaning off of BiPAP, IV Solu-Medrol, systemic antibiotics with doxycycline and Rocephin, as well as meter dose inhalers with albuterol, Symbicort, and Spiriva.  She was also treated with 5 days of remdesivir intravenously.   By discharge she was feeling back to her usual level of function, with a pulse oximetry in the upper 90s on 1 L of oxygen.  She does use oxygen at home more on a p.r.n. basis.  She was felt to be stable for discharge with the following changes in her medications.
Age: 80.0
Sex: F
Vaccine: FLUA4
Symptoms: Dyspnoea, Fibrin D dimer increased, Interstitial lung disease, Loss of personal independence in daily activities, Lung consolidation
Clinical narrative: Discharge Provider:  Primary Care Provider:  Admission Date: 5/7/2022 Discharge Date: May 12, 2022  PRESENTING PROBLEM: Acute respiratory failure with hypoxia [J96.01] Type 2 myocardial infarction [I21.A1] Acute hypoxemic respiratory failure due to COVID-19 [U07.1, J96.01] COVID-19 virus infection [U07.1]   HOSPITAL COURSE:   This is an 80-year-old female patient who presented with a 5 day history of cough and progressive shortness of breath which escalated on the morning of admission.  At home she had pulse oximetry reading that were severely low, along with profound tachypnea and severe coughing paroxysms.  Her daughter called EMS immediately and EMS found her pulse oximetry reading to be 50% on increase in her supplemental oxygen.  They placed her on BIPAP because of the severity of her dyspnea and her pulse oximetry readings and brought her to ED.  The patient's BIPAP was maintained with an FiO2 of 100%.  She was given Solumedrol and Nebulizer treatments.  She tested + for COVID.  She is vaccinated and has received a booster.  She had an elevated D dimer which prompted a CTA of the thorax that revealed bilateral interstitial pneumonia, ? Consolidative process, previous lobectomies from lung adenocarcinoma, and bronchial inflammation, but no pulmonary embolism.   She was admitted and treated with oxygen therapy after weaning off of BiPAP, IV Solu-Medrol, systemic antibiotics with doxycycline and Rocephin, as well as meter dose inhalers with albuterol, Symbicort, and Spiriva.  She was also treated with 5 days of remdesivir intravenously.   By discharge she was feeling back to her usual level of function, with a pulse oximetry in the upper 90s on 1 L of oxygen.  She does use oxygen at home more on a p.r.n. basis.  She was felt to be stable for discharge with the following changes in her medications.
Age: 80.0
Sex: F
Vaccine: FLUA4
Symptoms: Oxygen saturation decreased, Pneumonia, Positive airway pressure therapy, SARS-CoV-2 test positive, Tachypnoea
Clinical narrative: Discharge Provider:  Primary Care Provider:  Admission Date: 5/7/2022 Discharge Date: May 12, 2022  PRESENTING PROBLEM: Acute respiratory failure with hypoxia [J96.01] Type 2 myocardial infarction [I21.A1] Acute hypoxemic respiratory failure due to COVID-19 [U07.1, J96.01] COVID-19 virus infection [U07.1]   HOSPITAL COURSE:   This is an 80-year-old female patient who presented with a 5 day history of cough and progressive shortness of breath which escalated on the morning of admission.  At home she had pulse oximetry reading that were severely low, along with profound tachypnea and severe coughing paroxysms.  Her daughter called EMS immediately and EMS found her pulse oximetry reading to be 50% on increase in her supplemental oxygen.  They placed her on BIPAP because of the severity of her dyspnea and her pulse oximetry readings and brought her to ED.  The patient's BIPAP was maintained with an FiO2 of 100%.  She was given Solumedrol and Nebulizer treatments.  She tested + for COVID.  She is vaccinated and has received a booster.  She had an elevated D dimer which prompted a CTA of the thorax that revealed bilateral interstitial pneumonia, ? Consolidative process, previous lobectomies from lung adenocarcinoma, and bronchial inflammation, but no pulmonary embolism.   She was admitted and treated with oxygen therapy after weaning off of BiPAP, IV Solu-Medrol, systemic antibiotics with doxycycline and Rocephin, as well as meter dose inhalers with albuterol, Symbicort, and Spiriva.  She was also treated with 5 days of remdesivir intravenously.   By discharge she was feeling back to her usual level of function, with a pulse oximetry in the upper 90s on 1 L of oxygen.  She does use oxygen at home more on a p.r.n. basis.  She was felt to be stable for discharge with the following changes in her medications.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature increased, COVID-19, Chills, Cough
Clinical narrative: within 24 hours developed usual side effects experienced with previous vaccines - chills, low grade temp (99 - 100), muscle and joint aches, fatigue.  Symptoms worsened over next 2 days - temp 100.1, extreme fatigue, cough, nasal congestion, sore throat.  On 4/24 I did a home covid test and it was positive.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Myalgia, Nasal congestion, Oropharyngeal pain, SARS-CoV-2 test positive
Clinical narrative: within 24 hours developed usual side effects experienced with previous vaccines - chills, low grade temp (99 - 100), muscle and joint aches, fatigue.  Symptoms worsened over next 2 days - temp 100.1, extreme fatigue, cough, nasal congestion, sore throat.  On 4/24 I did a home covid test and it was positive.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure increased, Cardiac monitoring, Condition aggravated, Electrocardiogram normal, Heart rate increased
Clinical narrative: About 3 weeks after receiving my fourth dose of the vaccine, I woke up with a racing heart rate. It was so fast, I was not able to count the beats. My son tried also, but he was not able to either. I called for an ambulance, but by the time they got there, my heart rate had slowed a little. It was still high, as well as my blood pressure when they checked it. I made an appointment with my Cardiologist and he has me wearing a heart monitor which I will take back tomorrow. I had an EKG done and everything was fine.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Palpitations
Clinical narrative: About 3 weeks after receiving my fourth dose of the vaccine, I woke up with a racing heart rate. It was so fast, I was not able to count the beats. My son tried also, but he was not able to either. I called for an ambulance, but by the time they got there, my heart rate had slowed a little. It was still high, as well as my blood pressure when they checked it. I made an appointment with my Cardiologist and he has me wearing a heart monitor which I will take back tomorrow. I had an EKG done and everything was fine.
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Atelectasis, Barrett's oesophagus, Blood culture, COVID-19
Clinical narrative: Discharge Provider:  DO Primary Care Provider at Discharge: MD Admission Date: 5/7/2022 Discharge Date: 5/11/2022  DISCHARGE DIAGNOSES: 1. Acute hypoxemic respiratory failure due to COVID-19 pneumonia 2. Mild pulmonary fibrosis 3. Type 2 diabetes mellitus 4. Gout 5. GERD with Barrett's esophagus 6. Coronary artery disease s/p CABG 7. Hyperlipidemia  HOSPITAL COURSE: Patient is a 83 y.o. male with past medical history significant for hypertension, coronary artery disease, history CABG, hyperlipidemia, diabetes, mild pulmonary fibrosis, history of prostate cancer, Barrett's esophagus, GERD who was brought into the emergency department via EMS for 5 days of shortness of breath, cough with clear sputum production, decreased appetite, but diarrhea and tiredness. He has been vaccinated and boosted for COVID-19.    Upon arrival to the emergency department, he was satting at mid-upper 80s on room air and required 2 L O2.  He was also febrile.  He was originally thought to be septic-- sepsis workup initiated.  Blood cultures obtained, urine culture ordered.  He was given empiric Rocephin and Zithromax.  COVID test came back positive.  He was given 6 mg of Decadron IV, Tylenol 1000 mg, total of 2.5 L IVF.  Also given an albuterol, DuoNeb.  Chest x-ray shows patchy infiltrates without any lobar consolidation and mid left lung base atelectasis.  EKG showed tachycardia.    Patient was admitted and was given dexamethasone and remdesivir.  Patient's oxygen saturations slowly improved.  Blood cultures done in the emergency room came back positive, but identified as Staph hominis and Staph epidermidis, both of which can be considered contaminants.  Repeat blood cultures have remained negative.   He was markedly improved on day of discharge, 5/11/2022.  He can continue with symptomatic treatment following discharge, including Mucinex 600 mg PO BID and anti-tussives as needed.  He can follow-up with his PCP in 1 week.  He will be followed by the hospital-at-home program, as well as home health care following discharge as well.
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19 pneumonia, Chest X-ray abnormal, Coronary artery disease, Culture urine, Decreased appetite
Clinical narrative: Discharge Provider:  DO Primary Care Provider at Discharge: MD Admission Date: 5/7/2022 Discharge Date: 5/11/2022  DISCHARGE DIAGNOSES: 1. Acute hypoxemic respiratory failure due to COVID-19 pneumonia 2. Mild pulmonary fibrosis 3. Type 2 diabetes mellitus 4. Gout 5. GERD with Barrett's esophagus 6. Coronary artery disease s/p CABG 7. Hyperlipidemia  HOSPITAL COURSE: Patient is a 83 y.o. male with past medical history significant for hypertension, coronary artery disease, history CABG, hyperlipidemia, diabetes, mild pulmonary fibrosis, history of prostate cancer, Barrett's esophagus, GERD who was brought into the emergency department via EMS for 5 days of shortness of breath, cough with clear sputum production, decreased appetite, but diarrhea and tiredness. He has been vaccinated and boosted for COVID-19.    Upon arrival to the emergency department, he was satting at mid-upper 80s on room air and required 2 L O2.  He was also febrile.  He was originally thought to be septic-- sepsis workup initiated.  Blood cultures obtained, urine culture ordered.  He was given empiric Rocephin and Zithromax.  COVID test came back positive.  He was given 6 mg of Decadron IV, Tylenol 1000 mg, total of 2.5 L IVF.  Also given an albuterol, DuoNeb.  Chest x-ray shows patchy infiltrates without any lobar consolidation and mid left lung base atelectasis.  EKG showed tachycardia.    Patient was admitted and was given dexamethasone and remdesivir.  Patient's oxygen saturations slowly improved.  Blood cultures done in the emergency room came back positive, but identified as Staph hominis and Staph epidermidis, both of which can be considered contaminants.  Repeat blood cultures have remained negative.   He was markedly improved on day of discharge, 5/11/2022.  He can continue with symptomatic treatment following discharge, including Mucinex 600 mg PO BID and anti-tussives as needed.  He can follow-up with his PCP in 1 week.  He will be followed by the hospital-at-home program, as well as home health care following discharge as well.
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Diarrhoea, Dyspnoea, Electrocardiogram abnormal, Fatigue, Gastrooesophageal reflux disease
Clinical narrative: Discharge Provider:  DO Primary Care Provider at Discharge: MD Admission Date: 5/7/2022 Discharge Date: 5/11/2022  DISCHARGE DIAGNOSES: 1. Acute hypoxemic respiratory failure due to COVID-19 pneumonia 2. Mild pulmonary fibrosis 3. Type 2 diabetes mellitus 4. Gout 5. GERD with Barrett's esophagus 6. Coronary artery disease s/p CABG 7. Hyperlipidemia  HOSPITAL COURSE: Patient is a 83 y.o. male with past medical history significant for hypertension, coronary artery disease, history CABG, hyperlipidemia, diabetes, mild pulmonary fibrosis, history of prostate cancer, Barrett's esophagus, GERD who was brought into the emergency department via EMS for 5 days of shortness of breath, cough with clear sputum production, decreased appetite, but diarrhea and tiredness. He has been vaccinated and boosted for COVID-19.    Upon arrival to the emergency department, he was satting at mid-upper 80s on room air and required 2 L O2.  He was also febrile.  He was originally thought to be septic-- sepsis workup initiated.  Blood cultures obtained, urine culture ordered.  He was given empiric Rocephin and Zithromax.  COVID test came back positive.  He was given 6 mg of Decadron IV, Tylenol 1000 mg, total of 2.5 L IVF.  Also given an albuterol, DuoNeb.  Chest x-ray shows patchy infiltrates without any lobar consolidation and mid left lung base atelectasis.  EKG showed tachycardia.    Patient was admitted and was given dexamethasone and remdesivir.  Patient's oxygen saturations slowly improved.  Blood cultures done in the emergency room came back positive, but identified as Staph hominis and Staph epidermidis, both of which can be considered contaminants.  Repeat blood cultures have remained negative.   He was markedly improved on day of discharge, 5/11/2022.  He can continue with symptomatic treatment following discharge, including Mucinex 600 mg PO BID and anti-tussives as needed.  He can follow-up with his PCP in 1 week.  He will be followed by the hospital-at-home program, as well as home health care following discharge as well.
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Gout, Hyperlipidaemia, Lung infiltration, Productive cough, Pulmonary fibrosis
Clinical narrative: Discharge Provider:  DO Primary Care Provider at Discharge: MD Admission Date: 5/7/2022 Discharge Date: 5/11/2022  DISCHARGE DIAGNOSES: 1. Acute hypoxemic respiratory failure due to COVID-19 pneumonia 2. Mild pulmonary fibrosis 3. Type 2 diabetes mellitus 4. Gout 5. GERD with Barrett's esophagus 6. Coronary artery disease s/p CABG 7. Hyperlipidemia  HOSPITAL COURSE: Patient is a 83 y.o. male with past medical history significant for hypertension, coronary artery disease, history CABG, hyperlipidemia, diabetes, mild pulmonary fibrosis, history of prostate cancer, Barrett's esophagus, GERD who was brought into the emergency department via EMS for 5 days of shortness of breath, cough with clear sputum production, decreased appetite, but diarrhea and tiredness. He has been vaccinated and boosted for COVID-19.    Upon arrival to the emergency department, he was satting at mid-upper 80s on room air and required 2 L O2.  He was also febrile.  He was originally thought to be septic-- sepsis workup initiated.  Blood cultures obtained, urine culture ordered.  He was given empiric Rocephin and Zithromax.  COVID test came back positive.  He was given 6 mg of Decadron IV, Tylenol 1000 mg, total of 2.5 L IVF.  Also given an albuterol, DuoNeb.  Chest x-ray shows patchy infiltrates without any lobar consolidation and mid left lung base atelectasis.  EKG showed tachycardia.    Patient was admitted and was given dexamethasone and remdesivir.  Patient's oxygen saturations slowly improved.  Blood cultures done in the emergency room came back positive, but identified as Staph hominis and Staph epidermidis, both of which can be considered contaminants.  Repeat blood cultures have remained negative.   He was markedly improved on day of discharge, 5/11/2022.  He can continue with symptomatic treatment following discharge, including Mucinex 600 mg PO BID and anti-tussives as needed.  He can follow-up with his PCP in 1 week.  He will be followed by the hospital-at-home program, as well as home health care following discharge as well.
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, SARS-CoV-2 test positive, Staphylococcus test positive, Tachycardia, Type 2 diabetes mellitus
Clinical narrative: Discharge Provider:  DO Primary Care Provider at Discharge: MD Admission Date: 5/7/2022 Discharge Date: 5/11/2022  DISCHARGE DIAGNOSES: 1. Acute hypoxemic respiratory failure due to COVID-19 pneumonia 2. Mild pulmonary fibrosis 3. Type 2 diabetes mellitus 4. Gout 5. GERD with Barrett's esophagus 6. Coronary artery disease s/p CABG 7. Hyperlipidemia  HOSPITAL COURSE: Patient is a 83 y.o. male with past medical history significant for hypertension, coronary artery disease, history CABG, hyperlipidemia, diabetes, mild pulmonary fibrosis, history of prostate cancer, Barrett's esophagus, GERD who was brought into the emergency department via EMS for 5 days of shortness of breath, cough with clear sputum production, decreased appetite, but diarrhea and tiredness. He has been vaccinated and boosted for COVID-19.    Upon arrival to the emergency department, he was satting at mid-upper 80s on room air and required 2 L O2.  He was also febrile.  He was originally thought to be septic-- sepsis workup initiated.  Blood cultures obtained, urine culture ordered.  He was given empiric Rocephin and Zithromax.  COVID test came back positive.  He was given 6 mg of Decadron IV, Tylenol 1000 mg, total of 2.5 L IVF.  Also given an albuterol, DuoNeb.  Chest x-ray shows patchy infiltrates without any lobar consolidation and mid left lung base atelectasis.  EKG showed tachycardia.    Patient was admitted and was given dexamethasone and remdesivir.  Patient's oxygen saturations slowly improved.  Blood cultures done in the emergency room came back positive, but identified as Staph hominis and Staph epidermidis, both of which can be considered contaminants.  Repeat blood cultures have remained negative.   He was markedly improved on day of discharge, 5/11/2022.  He can continue with symptomatic treatment following discharge, including Mucinex 600 mg PO BID and anti-tussives as needed.  He can follow-up with his PCP in 1 week.  He will be followed by the hospital-at-home program, as well as home health care following discharge as well.
Age: 63.0
Sex: F
Vaccine: UNK
Symptoms: Eczema
Clinical narrative: Ezcema
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site pain, Muscular weakness, Pain, Pain in extremity
Clinical narrative: Pain and Muscle weakness in left arm and shoulder.  Pulsating throbbing pain in left Deltoid and Shoulder.  Aleve not effective for pain relief. Pain scale 7/10.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea, Oxygen saturation decreased
Clinical narrative: called man down (emergency) for dyspnea on thursday morning. VS- o2-88%, heartrate- 142, 156/98. o2 dropped to 73%- 3L O2 started then O2 sat at 87%. Per provider, sent to ER.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Activated partial thromboplastin time normal, Alanine aminotransferase normal, Albumin globulin ratio, Anion gap, Aspartate aminotransferase normal
Clinical narrative: COVID 19 BREAKTHROUGH: 69 y/o female presents to the ED at Hospital with the CC of: Severe weakness. Patient with PMH of HTN, HLD, CKD, and PMR presents today due to Severe weakness. Pt states she has had cough, congestion and SOB for about a month now and was treated for a sinus infection 1 month ago. Pt states she woke up this morning around 0500 due to cough and the cough was so severe that it made her vomit. Pt denies any CP, fever, nausea or diarrhea associated. Pt is fully vaccinated for COVID-19. In ED CXR completed and revealed bilateral opacities, concerning for atypical  pneumonia. Abnormal labs included; k 3.3, Co2 22, bun 27,  wbc 17.87, plt 376, bnp 2754, troponin 197 Pt given decadron in ED.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Basophil count normal, Basophil percentage decreased, Bilirubin conjugated, Blood albumin normal
Clinical narrative: COVID 19 BREAKTHROUGH: 69 y/o female presents to the ED at Hospital with the CC of: Severe weakness. Patient with PMH of HTN, HLD, CKD, and PMR presents today due to Severe weakness. Pt states she has had cough, congestion and SOB for about a month now and was treated for a sinus infection 1 month ago. Pt states she woke up this morning around 0500 due to cough and the cough was so severe that it made her vomit. Pt denies any CP, fever, nausea or diarrhea associated. Pt is fully vaccinated for COVID-19. In ED CXR completed and revealed bilateral opacities, concerning for atypical  pneumonia. Abnormal labs included; k 3.3, Co2 22, bun 27,  wbc 17.87, plt 376, bnp 2754, troponin 197 Pt given decadron in ED.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Blood alkaline phosphatase increased, Blood bilirubin normal, Blood calcium normal, Blood chloride normal, Blood creatine increased
Clinical narrative: COVID 19 BREAKTHROUGH: 69 y/o female presents to the ED at Hospital with the CC of: Severe weakness. Patient with PMH of HTN, HLD, CKD, and PMR presents today due to Severe weakness. Pt states she has had cough, congestion and SOB for about a month now and was treated for a sinus infection 1 month ago. Pt states she woke up this morning around 0500 due to cough and the cough was so severe that it made her vomit. Pt denies any CP, fever, nausea or diarrhea associated. Pt is fully vaccinated for COVID-19. In ED CXR completed and revealed bilateral opacities, concerning for atypical  pneumonia. Abnormal labs included; k 3.3, Co2 22, bun 27,  wbc 17.87, plt 376, bnp 2754, troponin 197 Pt given decadron in ED.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Blood glucose normal, Blood potassium decreased, Blood sodium normal, Blood urea increased, Brain natriuretic peptide increased
Clinical narrative: COVID 19 BREAKTHROUGH: 69 y/o female presents to the ED at Hospital with the CC of: Severe weakness. Patient with PMH of HTN, HLD, CKD, and PMR presents today due to Severe weakness. Pt states she has had cough, congestion and SOB for about a month now and was treated for a sinus infection 1 month ago. Pt states she woke up this morning around 0500 due to cough and the cough was so severe that it made her vomit. Pt denies any CP, fever, nausea or diarrhea associated. Pt is fully vaccinated for COVID-19. In ED CXR completed and revealed bilateral opacities, concerning for atypical  pneumonia. Abnormal labs included; k 3.3, Co2 22, bun 27,  wbc 17.87, plt 376, bnp 2754, troponin 197 Pt given decadron in ED.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Carbon dioxide decreased, Chest X-ray abnormal, Cough, Dyspnoea
Clinical narrative: COVID 19 BREAKTHROUGH: 69 y/o female presents to the ED at Hospital with the CC of: Severe weakness. Patient with PMH of HTN, HLD, CKD, and PMR presents today due to Severe weakness. Pt states she has had cough, congestion and SOB for about a month now and was treated for a sinus infection 1 month ago. Pt states she woke up this morning around 0500 due to cough and the cough was so severe that it made her vomit. Pt denies any CP, fever, nausea or diarrhea associated. Pt is fully vaccinated for COVID-19. In ED CXR completed and revealed bilateral opacities, concerning for atypical  pneumonia. Abnormal labs included; k 3.3, Co2 22, bun 27,  wbc 17.87, plt 376, bnp 2754, troponin 197 Pt given decadron in ED.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Eosinophil count normal, Eosinophil percentage, Globulins increased, Glomerular filtration rate decreased, Haematocrit decreased
Clinical narrative: COVID 19 BREAKTHROUGH: 69 y/o female presents to the ED at Hospital with the CC of: Severe weakness. Patient with PMH of HTN, HLD, CKD, and PMR presents today due to Severe weakness. Pt states she has had cough, congestion and SOB for about a month now and was treated for a sinus infection 1 month ago. Pt states she woke up this morning around 0500 due to cough and the cough was so severe that it made her vomit. Pt denies any CP, fever, nausea or diarrhea associated. Pt is fully vaccinated for COVID-19. In ED CXR completed and revealed bilateral opacities, concerning for atypical  pneumonia. Abnormal labs included; k 3.3, Co2 22, bun 27,  wbc 17.87, plt 376, bnp 2754, troponin 197 Pt given decadron in ED.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Haemoglobin decreased, Influenza A virus test negative, Influenza B virus test, International normalised ratio increased, Lung opacity
Clinical narrative: COVID 19 BREAKTHROUGH: 69 y/o female presents to the ED at Hospital with the CC of: Severe weakness. Patient with PMH of HTN, HLD, CKD, and PMR presents today due to Severe weakness. Pt states she has had cough, congestion and SOB for about a month now and was treated for a sinus infection 1 month ago. Pt states she woke up this morning around 0500 due to cough and the cough was so severe that it made her vomit. Pt denies any CP, fever, nausea or diarrhea associated. Pt is fully vaccinated for COVID-19. In ED CXR completed and revealed bilateral opacities, concerning for atypical  pneumonia. Abnormal labs included; k 3.3, Co2 22, bun 27,  wbc 17.87, plt 376, bnp 2754, troponin 197 Pt given decadron in ED.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphocyte count, Lymphocyte percentage decreased, Mean cell haemoglobin concentration normal, Mean cell haemoglobin normal, Mean cell volume normal
Clinical narrative: COVID 19 BREAKTHROUGH: 69 y/o female presents to the ED at Hospital with the CC of: Severe weakness. Patient with PMH of HTN, HLD, CKD, and PMR presents today due to Severe weakness. Pt states she has had cough, congestion and SOB for about a month now and was treated for a sinus infection 1 month ago. Pt states she woke up this morning around 0500 due to cough and the cough was so severe that it made her vomit. Pt denies any CP, fever, nausea or diarrhea associated. Pt is fully vaccinated for COVID-19. In ED CXR completed and revealed bilateral opacities, concerning for atypical  pneumonia. Abnormal labs included; k 3.3, Co2 22, bun 27,  wbc 17.87, plt 376, bnp 2754, troponin 197 Pt given decadron in ED.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Mean platelet volume normal, Monocyte count increased, Monocyte percentage increased, N-terminal prohormone brain natriuretic peptide increased, Neutrophil count increased
Clinical narrative: COVID 19 BREAKTHROUGH: 69 y/o female presents to the ED at Hospital with the CC of: Severe weakness. Patient with PMH of HTN, HLD, CKD, and PMR presents today due to Severe weakness. Pt states she has had cough, congestion and SOB for about a month now and was treated for a sinus infection 1 month ago. Pt states she woke up this morning around 0500 due to cough and the cough was so severe that it made her vomit. Pt denies any CP, fever, nausea or diarrhea associated. Pt is fully vaccinated for COVID-19. In ED CXR completed and revealed bilateral opacities, concerning for atypical  pneumonia. Abnormal labs included; k 3.3, Co2 22, bun 27,  wbc 17.87, plt 376, bnp 2754, troponin 197 Pt given decadron in ED.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Neutrophil percentage increased, Platelet count normal, Protein total normal, Prothrombin time prolonged, Red blood cell count decreased
Clinical narrative: COVID 19 BREAKTHROUGH: 69 y/o female presents to the ED at Hospital with the CC of: Severe weakness. Patient with PMH of HTN, HLD, CKD, and PMR presents today due to Severe weakness. Pt states she has had cough, congestion and SOB for about a month now and was treated for a sinus infection 1 month ago. Pt states she woke up this morning around 0500 due to cough and the cough was so severe that it made her vomit. Pt denies any CP, fever, nausea or diarrhea associated. Pt is fully vaccinated for COVID-19. In ED CXR completed and revealed bilateral opacities, concerning for atypical  pneumonia. Abnormal labs included; k 3.3, Co2 22, bun 27,  wbc 17.87, plt 376, bnp 2754, troponin 197 Pt given decadron in ED.